LUMA Vision Expands Clinical Use of VERAFEYE™ in Guiding AF Ablations and Completes Key 510k Submission.

Contributed by: PR Newswire

Images

PR Newswire associated0

PR Newswire associated1

Tags

LUMA-VERAFEYE

More Like This

PR Newswire associated0

Precision Redefined: LUMA Vision Completes VERAFEYE™ 4D-Guided Persistent AF Ablations, Demonstrating a Significant Advancement in Simplifying Image-Guided Cardiac Care

PR Newswire associated0

LUMA Vision Successfully Completes First-in-Human Procedures with its Novel VERAFEYE™ Navigation and Visualization Platform

PR Newswire associated0

LUMA Vision Receives FDA Clearance for VERAFEYE 2D/4D Cardiac Visualization Platform

LUMA Vision Co-Founders, CEO Fionn Lahart (right) and Chief Technology Officer Christoph Hennersperger (left). (Photo: Business Wire)

LUMA Vision Announces $22 Million in New Financing to Secure FDA Approval and Advance Development of 4D Cardiac Imaging and Navigation Platform

MedLumics New CEO and Board Member Announces 10 Patients Treated in First in Man (FIM) Clinical Trial With the Real-Time Visually Guided AblaView PFA System

PR Newswire associated0

Adagio Medical Announces CE Mark approval of VT Cryoablation System, Plans for Immediate Commercialization in Select European Centers

PR Newswire associated0

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE™ Pulsed Field Ablation (PFA) Platform

LumiThera Obtains FDA Authorization of Valeda Treatment for Dry AMD Patients to Improve Vision